Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
Verified American Company Independently reviewed and approved · June 2026

ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

$85.60 -1.36% NASDAQ: ARWR · 15-min delayed
  • PASADENA, California
  • Public · NASDAQ: ARWR
  • 711 employees
$10.3BMarket cap
$829.4MRevenue · FY2025
-$1.6MNet income
711Employees
ARWRNASDAQ
1995IPO

About ARROWHEAD PHARMACEUTICALS, INC.

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

American Credentials

Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →

Reported figures

Financial summary

Revenue FY2025
$829.4M
Net income
-$1.6M
Total assets
$1.4B
Market cap
$10.3B
Operating margin
11.9%
Net margin
3.6%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$829.4M
Operating expenses
$731.1M
Operating income
$98.3M
Income tax
$21.4M
Net income
$30.1M
EPS (basic)
$-0.01
EPS (diluted)
$-0.01

Balance sheet

Total assets
$1.4B
Current assets
$950.6M
Total liabilities
$881.9M
Current liabilities
$195.5M
Shareholders’ equity
$503.4M

Cash flow

Operating cash flow
$179.6M
Investing cash flow
-$129.3M
Financing cash flow
$74.0M
Net cash flow
$123.9M

Statements via Polygon.io (SEC filings)

NASDAQ: ARWR
$85.60 -1.36%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$14.71 $88.70

52-week range

Market cap
$10.3B
EPS (diluted)
$-0.01
Shares outstanding
120.3M
Open
Day range
Prev close
Volume
IPO date
Feb 1, 1995

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price

  • Reported a net loss of $1.6M in FY2025.
  • Revenue grew 500% from FY2021 to FY2025.
  • Trading near its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review ARROWHEAD PHARMACEUTICALS, INC..

Write a review
Newsroom

News about ARROWHEAD PHARMACEUTICALS, INC.

News & sentiment via Polygon.io

FAQ

Arrowhead Pharmaceuticals, Inc.: frequently asked questions

Is Arrowhead Pharmaceuticals, Inc. an American company?

Yes — Arrowhead Pharmaceuticals, Inc. is an American company headquartered in Pasadena, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.

Where is Arrowhead Pharmaceuticals, Inc. headquartered?

Arrowhead Pharmaceuticals, Inc. is headquartered in Pasadena, California, United States.

Is Arrowhead Pharmaceuticals, Inc. publicly traded?

Yes — Arrowhead Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol ARWR on the NASDAQ.

What does Arrowhead Pharmaceuticals, Inc. do?

Arrowhead Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →